|
|
|
|
|
|
|
|
pharma press release
Multi-center
study of 100-120 patients, evaluating pre- and post-treatment of LB1148
administered orally for major abdominal surgeries. Enrollment expected
to begin in August 2016. For ileus, the study will measure the number of
hours from surgical closure to resolution of postoperative ileus via
various returning gastrointestinal functions. Length of stay will also
be measured. For adhesions, study will evaluate whether LB1148 reduces
the number of surgical adhesions formed in certain types of abdominal
surgeries where a 2nd operation is required.
clincialtrials.gov:
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection (PROFILE)
Verified August 2016 by Leading BioSciences, Inc
Sponsor:
Leading BioSciences, Inc
Information provided by (Responsible Party):
Leading BioSciences, Inc
ClinicalTrials.gov Identifier:
NCT02836470
First received: July 13, 2016
Last updated: August 29, 2016
Last verified: August 2016
Criteria
Inclusion Criteria:
- Scheduled to undergo an elective (non-emergent) bowel resection with or without a planned stoma via laparotomy or minimally invasive technique. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elected indication.
Contacts
Contact: Thomas M Hallam, PhD | 858.704.4900 | tom.hallam@leadingbiosciences.com |
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.